What are the guidelines for using Norethindrone (progestin) for contraception, menopausal symptoms, or endometriosis?

Norethindrone Guidelines for Contraception, Menopausal Symptoms, and Endometriosis

Contraception

Progestin-only pills containing norethindrone carry no increased stroke risk and are highly effective contraceptive options, particularly for women with contraindications to estrogen-containing formulations. 1

Dosing and Administration

• Take one tablet daily at the same time every day without interruption between pill packs 2
• Continuous administration is essential—no pill-free intervals 2
• If a pill is taken ≥3 hours late, use backup contraception (condoms/spermicides) for the next 48 hours 2

Contraceptive Effectiveness

• Progestin-only pills (norethindrone or drospirenone) have <90% effectiveness with typical use, lower than combined oral contraceptives (93-97%) 1
• Norethindrone prevents pregnancy by suppressing ovulation in approximately 50% of users, thickening cervical mucus, and altering the endometrium 2

Stroke Risk Profile

• Norethindrone-containing progestin-only pills have NO increased stroke risk, unlike combined hormonal contraceptives containing estrogen 1
• This makes them particularly suitable for women with migraine with aura, hypertension, smoking history, or other stroke risk factors 1

Baseline and Ongoing Monitoring

• Before initiation: Verify pregnancy status (Category X contraindication) and measure blood pressure 3
• Ongoing: Monitor blood pressure and assess for health status changes 3
• Annual clinical review for stable patients, with more frequent monitoring during initial therapy 3

---

Combined Oral Contraceptives (Norethindrone + Ethinyl Estradiol)

When norethindrone is combined with ethinyl estradiol, it provides effective contraception AND FDA-approved acne treatment, but carries mild stroke risk that must be weighed against benefits. 1

FDA-Approved Formulation for Acne

• Norethindrone acetate/ethinyl estradiol/ferrous fumarate is FDA-approved for acne treatment in women desiring contraception 1
• Dosing: One pill daily for 21 days followed by 7 days off 3
• The American Academy of Dermatology conditionally recommends combined oral contraceptives for acne based on moderate-certainty evidence showing 45% greater IGA success versus placebo 1

Stroke Risk Considerations

• Combined oral contraceptives containing ethinyl estradiol carry mild increased stroke risk (+) compared to progestin-only formulations 1
• Risk increases linearly with estrogen dose: OR 1.19 per 10 μg ethinyl estradiol 1
• Contraindications: Migraine with aura, uncontrolled hypertension, smoking (especially age >35), history of stroke/VTE 1

---

Menopausal Hormone Therapy

For postmenopausal women with premature ovarian insufficiency or early menopause, norethindrone serves as endometrial protection when combined with estrogen, with micronized progesterone preferred as first-line but norethindrone as an acceptable alternative. 1

Progestin Selection and Dosing

Sequential regimens (for women desiring withdrawal bleeding):

• Norethindrone (norethisterone): 5 mg daily for 12-14 days per 28-day cycle when combined with transdermal or oral estradiol 1
• This is a second-choice option; micronized progesterone 100-200 mg daily for 12-14 days is preferred due to lower cardiovascular and VTE risk 1

Continuous regimens (for women avoiding withdrawal bleeding):

• Norethindrone: Minimum 1 mg daily when combined with continuous estrogen 1
• Alternative continuous doses: 2.5 mg MPA or 5 mg dydrogesterone daily 1

Clinical Context for Use

• Norethindrone is appropriate for women with premature ovarian insufficiency (menopause <40 years) or early menopause (<45 years) who require hormone therapy until average menopause age (45-55 years) 1
• Avoid progestins with anti-androgenic effects in women with iatrogenic POI who may have hypoandrogenism and sexual dysfunction 1

Monitoring Requirements

• Baseline: Assess for breast cancer history (contraindication) 3
• Periodic liver function tests for doses ≥10 mg daily: every 3-6 months initially, then annually if stable 3
• Annual clinical review for stable patients 3

Important Contraindications

• Women ≥60 years or >10 years post-menopause: Oral estrogen-containing HT carries excess stroke risk (Class 3 recommendation—harm) 1
• History of breast cancer is an absolute contraindication 3

---

Endometriosis

Norethindrone acetate demonstrates 94% overall pain relief in symptomatic endometriosis, making it a cost-effective treatment option despite breakthrough bleeding in over half of patients. 4

Efficacy Data

• Dysmenorrhea relief: 92.3% of patients (48/52) 4
• Noncyclic pelvic pain relief: 89.2% of patients (25/28) 4
• Overall treatment success: 84.5% of patients (44/52) completed treatment successfully 4

Side Effects and Discontinuation

• Breakthrough bleeding occurs in 57.6% of patients but only causes 7.7% to discontinue 4
• Other discontinuation reasons: severe breast tenderness (1 patient), persistent pelvic pain (3 patients) 4

---

Drug Interactions and Special Considerations

Medications That Reduce Contraceptive Effectiveness

• Enzyme inducers: Rifampin, barbiturates, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate, griseofulvin 2
• Anti-HIV protease inhibitors: Variable effects on hormone levels 2
• St. John's Wort: Induces hepatic enzymes and may cause breakthrough bleeding 2

Gastrointestinal Issues

• Diarrhea and/or vomiting may reduce hormone absorption—consider backup contraception during acute illness 2

Laboratory Test Alterations

• Decreased sex hormone-binding globulin (SHBG) 2
• Decreased thyroxine concentrations due to reduced thyroid binding globulin 2

Return to Fertility

• Rapid return of normal ovulation following discontinuation of progestin-only contraceptives 2

---

Key Clinical Pitfalls

• Timing is critical: Even 3+ hours late requires backup contraception for 48 hours 2
• Pregnancy must be ruled out before initiating any norethindrone therapy (Category X) 3, 2
• Do not confuse progestin-only pills with combined oral contraceptives—stroke risk profiles differ dramatically 1
• Breakthrough bleeding is expected and does not indicate treatment failure, particularly in endometriosis treatment 4
• Headache/migraine with new pattern requires discontinuation and evaluation 2